Heat shock protein inhibitors for the treatment of fungal infections

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Invasive fungal infections are a leading cause of mortality, especially in immunocompromised patients. Therapy is made difficult by the limited number of antifungal agents currently available which mostly target ergosterol in fungal cell membranes. The paucity of targets allows the development of cross resistance to all drugs with a common target. This highlights the need to develop new therapeutic strategies for fungal disease including agents with novel mechanisms of action. Heat shock protein 90 stabilizes calcineurin which regulates response to stress, allowing for calcineurin dependent stress responses required to survive exposure to antifungal drugs. Heat shock protein 90 inhibition abrogates calcineurin dependent stress responses, changing fungistatic drugs to fungicidal. Targeting a highly conserved protein that has a vital role in many cellular signaling pathways, reduces the potential for emergence of resistance to heat shock proteins inhibitors. This article will review recent patents in novel heat shock protein inhibitor therapy, such as efungumab, which diminish the emergence of antifungal drug resistance and enable greater efficacy of existing antifungals.

Original languageEnglish (US)
Pages (from-to)38-44
Number of pages7
JournalRecent Patents on Anti-Infective Drug Discovery
Volume6
Issue number1
DOIs
StatePublished - Feb 9 2011

Fingerprint

Mycoses
Calcineurin
Heat-Shock Proteins
HSP90 Heat-Shock Proteins
Fungal Drug Resistance
Pharmaceutical Preparations
Ergosterol
Patents
Antifungal Agents
Immunocompromised Host
Therapeutics
Cell Membrane
Mortality
Proteins

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

@article{11f14aa9b45343ce8d80906cf11db857,
title = "Heat shock protein inhibitors for the treatment of fungal infections",
abstract = "Invasive fungal infections are a leading cause of mortality, especially in immunocompromised patients. Therapy is made difficult by the limited number of antifungal agents currently available which mostly target ergosterol in fungal cell membranes. The paucity of targets allows the development of cross resistance to all drugs with a common target. This highlights the need to develop new therapeutic strategies for fungal disease including agents with novel mechanisms of action. Heat shock protein 90 stabilizes calcineurin which regulates response to stress, allowing for calcineurin dependent stress responses required to survive exposure to antifungal drugs. Heat shock protein 90 inhibition abrogates calcineurin dependent stress responses, changing fungistatic drugs to fungicidal. Targeting a highly conserved protein that has a vital role in many cellular signaling pathways, reduces the potential for emergence of resistance to heat shock proteins inhibitors. This article will review recent patents in novel heat shock protein inhibitor therapy, such as efungumab, which diminish the emergence of antifungal drug resistance and enable greater efficacy of existing antifungals.",
author = "Baldeep Wirk",
year = "2011",
month = "2",
day = "9",
doi = "10.2174/157489111794407840",
language = "English (US)",
volume = "6",
pages = "38--44",
journal = "Recent Patents on Anti-Infective Drug Discovery",
issn = "1574-891X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

Heat shock protein inhibitors for the treatment of fungal infections. / Wirk, Baldeep.

In: Recent Patents on Anti-Infective Drug Discovery, Vol. 6, No. 1, 09.02.2011, p. 38-44.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Heat shock protein inhibitors for the treatment of fungal infections

AU - Wirk, Baldeep

PY - 2011/2/9

Y1 - 2011/2/9

N2 - Invasive fungal infections are a leading cause of mortality, especially in immunocompromised patients. Therapy is made difficult by the limited number of antifungal agents currently available which mostly target ergosterol in fungal cell membranes. The paucity of targets allows the development of cross resistance to all drugs with a common target. This highlights the need to develop new therapeutic strategies for fungal disease including agents with novel mechanisms of action. Heat shock protein 90 stabilizes calcineurin which regulates response to stress, allowing for calcineurin dependent stress responses required to survive exposure to antifungal drugs. Heat shock protein 90 inhibition abrogates calcineurin dependent stress responses, changing fungistatic drugs to fungicidal. Targeting a highly conserved protein that has a vital role in many cellular signaling pathways, reduces the potential for emergence of resistance to heat shock proteins inhibitors. This article will review recent patents in novel heat shock protein inhibitor therapy, such as efungumab, which diminish the emergence of antifungal drug resistance and enable greater efficacy of existing antifungals.

AB - Invasive fungal infections are a leading cause of mortality, especially in immunocompromised patients. Therapy is made difficult by the limited number of antifungal agents currently available which mostly target ergosterol in fungal cell membranes. The paucity of targets allows the development of cross resistance to all drugs with a common target. This highlights the need to develop new therapeutic strategies for fungal disease including agents with novel mechanisms of action. Heat shock protein 90 stabilizes calcineurin which regulates response to stress, allowing for calcineurin dependent stress responses required to survive exposure to antifungal drugs. Heat shock protein 90 inhibition abrogates calcineurin dependent stress responses, changing fungistatic drugs to fungicidal. Targeting a highly conserved protein that has a vital role in many cellular signaling pathways, reduces the potential for emergence of resistance to heat shock proteins inhibitors. This article will review recent patents in novel heat shock protein inhibitor therapy, such as efungumab, which diminish the emergence of antifungal drug resistance and enable greater efficacy of existing antifungals.

UR - http://www.scopus.com/inward/record.url?scp=79551652182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551652182&partnerID=8YFLogxK

U2 - 10.2174/157489111794407840

DO - 10.2174/157489111794407840

M3 - Article

C2 - 21192778

AN - SCOPUS:79551652182

VL - 6

SP - 38

EP - 44

JO - Recent Patents on Anti-Infective Drug Discovery

JF - Recent Patents on Anti-Infective Drug Discovery

SN - 1574-891X

IS - 1

ER -